Neutralization potential of Covishield (AstraZeneca) vaccinated individuals against B.1.617.1

 Pragya D. Yadav, Gajanan N. Sapkal, Priya Abraham, Gururaj Deshpande, Dimpal A Nyayanit, Deepak Y. Patil, Nivedita Gupta, Rima R. Sahay, Anita M. Shete, Sanjay Kumar, Samiran Panda, Balram Bhargava

doi: https://doi.org/10.1101/2021.05.12.443645

This article is a preprint and has not been certified by peer review [what does this mean?].

PDF:  https://www.biorxiv.org/content/10.1101/2021.05.12.443645v1.full.pdf

Abstract

Covishield comprises the larger proportion in the vaccination program in India. Hence, it is of utmost importance to understand neutralizing capability of vaccine against the B.1.617.1 variant which is considered to responsible for surge of the cases in India. The neutralizing-antibody (NAb) titer against B.1.167.1 and prototype B.1 variant (D614G) was determined of the vaccine sera (4 weeks after second dose) of COVID-19 naïve subjects (n=43) and COVID-19 recovered subjects (n=18). The results demonstrated that sera of COVID-19 recovered subjects (n=18) who received two doses of Covishield have higher NAb response compared to the COVID-19 naive with a significant difference (p<0.0001) in NAb titer against B.1 and B.1.617.1 In-spite of reduction in the neutralizing titer against B.1.617.1 variant; Covishield vaccine-induced antibodies are likely to be protective to limit the severity and mortality of the disease in the vaccinated individuals.

Competing Interest Statement

The authors have declared no competing interest.

https://www.biorxiv.org/content/10.1101/2021.05.12.443645v1